Kuros Biosciences AG/ CH0325814116 /
15.11.2024 17:18:12 | Изменение -6.50 | Объем сделки | Бид17:20:00 | Предложение17:20:00 | Рыночная капитализация | Дивидендная доходность | Коэффициент Цена/Доход |
---|---|---|---|---|---|---|---|
25.00CHF | -20.63% | 19,018 Оборот: 491,952.55 |
-Величина цены спроса: - | -Величина цены предложения: - | 912.21 млнCHF | - | - |
GlobeNewswire
03.02.2022
Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal Indications
GlobeNewswire
28.09.2021
Kuros Biosciences to Showcase New MagnetOs Products at NASS 2021 Annual Meeting
GlobeNewswire
15.07.2021
Kuros to receive $7 million up front and potentially $166.5 million in future revenues under a royal...
GlobeNewswire
15.07.2021
XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Bioscie...
GlobeNewswire
02.03.2021
Kuros Biosciences Announces MagnetOs Sales and Distribution Agreements Across Northern Europe
GlobeNewswire
09.09.2020
CORRECTING AND REPLACING -- Kuros Biosciences’s Licensee Checkmate Pharmaceuticals Completes its IPO...
GlobeNewswire
09.09.2020
Kuros Biosciences’s licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ
GlobeNewswire
01.09.2020
Kuros Biosciences Announces Treatment of the First Patient in its Spinal Fusion Trial with Fibrin-PT...
GlobeNewswire
30.01.2020
Kuros Reports Publication of MagnetOs Preclinical Data Demonstrating Superiority to Market-Leading S...
GlobeNewswire
02.10.2019
Kuros Biosciences to Host Key Opinion Leader Meeting in Zurich Showcasing its Commercial Stage Advan...
GlobeNewswire
24.09.2019
Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North Americ...
GlobeNewswire
03.09.2019
Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Cli...
GlobeNewswire
09.07.2019
Kuros Biosciences Signs Agreement with Surgical Specialties on Distribution of MagnetOs in Australia...
GlobeNewswire
30.04.2019
Kuros Biosciences to Propose Re-Appointment of Chairman and Board Members at Annual General Meeting
GlobeNewswire
09.04.2019
Kuros Biosciences Enters Convertible Bond Financing Agreement For Up To CHF 5 Million
- Первая страница
- Назад
- 1
- 2
- Следующий
- Последняя страница